

# **FIRST LIGHT**

# RESEARCH

Escorts | Target: Rs 1,350 | +16% | BUY

Fundamentals in place; valuations attractive - upgrade to BUY

Balkrishna Industries | Target: Rs 1,550 | –18% | SELL Valuations rich; maintain SELL

Greenpanel Industries | Target: Rs 295 | +23% | BUY

Stellar performance, maintain BUY

Mphasis | Target: Rs 1,580 | -12% | SELL DXC drag to continue; cut to SELL

# SUMMARY

### Escorts

Escorts (ESC) reported Q4FY21 revenue of Rs 22bn (+60% YoY) with aboveexpected ASP. Near-term demand looks hazy due to the Covid wave, but we believe fundamental drivers are in place and expect a 6% volume CAGR for FY21-FY23. The construction equipment and rail businesses are also likely to provide steady support. We raise FY22-FY23 revenue/EPS by 7-8% each and move to a new Mar'22 TP of Rs 1,350 (vs. Rs 1,150), set at 15x P/E. After correcting 18% in three months, the stock is at an attractive 13x FY23E EPS – raise from SELL to BUY.

### Click here for the full report.

# **Balkrishna Industries**

Balkrishna Industries (BIL) posted healthy Q4FY21 volume growth of 17% YoY to 68k MT, 15% ahead of our projections. Revenue increased 29% YoY and EBITDA margin stood at 31% (+360bps YoY), beating estimates. Management has guided for robust 10-17% YoY tonnage volume growth in FY22 coupled with a stable margin at 28-30% despite RM cost headwinds. Baking in the higher volume guidance, we revise FY22/FY23 EPS up 22%/16% and our Mar'22 TP to Rs 1,550 (vs. Rs 1,340). Retain SELL on rich valuations at 27x FY23E EPS

### Click here for the full report.

17 May 2021

# **TOP PICKS**

LARGE-CAP IDEAS			
Company	Rating	Target	
<u>Cipla</u>	Buy	1,000	
<u>TCS</u>	Buy	3,780	
<u>Tech Mahindra</u>	Buy	1,190	

### MID-CAP IDEAS

Company	Rating	Target	
<u>Alkem Labs</u>	Buy	3,750	
Greenply Industries	Buy	195	
Laurus Labs	Buy	540	
Transport Corp	Buy	320	
Source: BOBCAPS Research			

#### DAILY MACRO INDICATORS

Indicator	Current	2D (%)	1M (%)	12M (%)
US 10Y yield (%)	1.66	(3bps)	(1bps)	104bps
India 10Y yield (%)	6.01	Obps	Obps	23bps
USD/INR	73.43	(0.1)	2.2	2.8
Brent Crude (US\$/bbl)	67.05	(3.3)	6.0	115.4
Dow	34,021	1.3	0.8	44.0
Shanghai	3,430	(1.0)	0.5	19.5
Sensex	48,691	(1.0)	1.7	56.4
India FII (US\$ mn)	11 May	MTD	CYTD	FYTD
FII-D	(24.3)	177.0	(2,215.3)	(188.0)
FII-E	97.5	(282.5)	5,554.7	(1,771.7)

Source: Bank of Baroda Economics Research

**BOBCAPS Research** research@bobcaps.in





# **Greenpanel Industries**

Greenpanel Industries' (GREENP) consolidated Q4FY21 revenue grew 64% YoY aided by a 63%/65% increase in the MDF/plywood segments. Operating margin (exforex gains) expanded 375bps YoY, spurring EBITDA growth of 93% YoY. Management has guided for further net debt reduction by Rs 1.5bn in FY22. We raise FY22-FY23 PAT by ~5% each and hike our target P/E to 18x (vs. 15x) due to material improvement in balance sheet, return ratios and profitability. Maintain BUY with a revised Mar'22 TP of Rs 295 (vs. Rs 235).

Click here for the full report.

# **Mphasis**

Mphasis (MPHL) reported dollar revenue growth of 1.8% QoQ in Q4FY21, underperforming our estimate. Growth was dragged down by a slow pickup in direct channel business, which grew 3% QoQ USD. EBIT margin at 16.1% (16.5% est.) declined 30bps QoQ. We prune FY22/FY23 EPS by 1%/2% and roll forward to a revised Mar'22 TP of Rs 1,580 (vs. Rs 1,550), based on an unchanged 17x P/E. Considering the laggardly performance vis-à-vis peers and non-renewal of DXC's MRC, we downgrade the stock to SELL (vs. REDUCE).

Click here for the full report.



# **BUY** TP: Rs 1,350 | A 16%

ESCORTS

Auto Components

# Fundamentals in place; valuations attractive – upgrade to BUY

Escorts (ESC) reported Q4FY21 revenue of Rs 22bn (+60% YoY) with aboveexpected ASP. Near-term demand looks hazy due to the Covid wave, but we believe fundamental drivers are in place and expect a 6% volume CAGR for FY21-FY23. The construction equipment and rail businesses are also likely to provide steady support. We raise FY22-FY23 revenue/EPS by 7-8% each and move to a new Mar'22 TP of Rs 1,350 (vs. Rs 1,150), set at 15x P/E. After correcting 18% in three months, the stock is at an attractive 13x FY23E EPS – raise from SELL to BUY.

**Revenue beat but RM cost inflation hits margins:** ESC's Q4 revenue of Rs 22bn (+60% YoY) was marginally above our estimate on better-thanexpected ASP (+6% QoQ). Operating margin contracted 245bps QoQ to 15.6%, ~70bps short of our estimate owing to a below-expected gross margin. EBITDA/adj. PAT grew 77%/93% YoY to Rs 3.4bn/Rs 2.7bn.

**Demand drivers in place:** After 26% YoY growth in FY21, we expect the domestic tractor industry to post a 6% volume CAGR over FY21-FY23 off a high base. Growth will be aided by a rising rural economy and aggressive infrastructure spends. ESC's construction and railway businesses (together 20% of revenue) continued to witness steady growth and improving margins in Q4.

**Valuations compelling; upgrade to BUY:** We raise FY22/FY23 revenue estimates ~8% each on higher realisations (input cost passthrough) and strong growth in other verticals, with EBITDA margin now forecast at 13.6% (vs. 13.5%) on better construction equipment margins. This leads to a ~7% rise in our EPS estimates. We now model for a revenue/EBITDA/PAT CAGR of 7%/-1%/7% over FY21-FY23. We reset our target FY23E P/E from 17x to 15x given the moderate growth outlook but upgrade to BUY as the stock is trading at attractive valuations of 13x FY23E EPS post an ~18% correction since Feb'21.

### **KEY FINANCIALS**

Y/E 31 Mar	FY19A	FY20A	FY21P	FY22E	FY23E
Total revenue (Rs mn)	62,620	58,101	70,144	75,370	80,770
EBITDA (Rs mn)	7,226	6,624	11,268	10,221	10,960
Adj. net profit (Rs mn)	4,789	4,825	8,724	8,583	9,835
Adj. EPS (Rs)	48.8	49.2	79.1	77.8	89.2
Adj. EPS growth (%)	38.0	0.8	64.4	(1.6)	14.6
Adj. ROAE (%)	17.9	15.5	17.7	15.0	14.8
Adj. P/E (x)	23.8	23.6	14.7	15.0	13.1
EV/EBITDA (x)	19.4	21.2	12.4	12.6	12.3

Source: Company, BOBCAPS Research | P - Provisional

Mayur Milak | Nishant Chowhan, CFA research@bobcaps.in

Ticker/Price	ESC IN/Rs 1,164
Market cap	US\$ 1.9bn
Shares o/s	123mn
3M ADV	US\$ 19.5mn
52wk high/low	Rs 1,468/Rs 799
Promoter/FPI/DII	40%/20%/10%
Source: NSE	

### STOCK PERFORMANCE









Valuations rich; maintain SELL

Balkrishna Industries (BIL) posted healthy Q4FY21 volume growth of 17% YoY to 68k MT, 15% ahead of our projections. Revenue increased 29% YoY and EBITDA margin stood at 31% (+360bps YoY), beating estimates. Management has guided for robust 10-17% YoY tonnage volume growth in FY22 coupled with a stable margin at 28-30% despite RM cost headwinds. Baking in the higher volume guidance, we revise FY22/FY23 EPS up 22%/16% and our Mar'22 TP to Rs 1,550 (vs. Rs 1,340). Retain SELL on rich valuations at 27x FY23E EPS.

**Operational beat in Q4:** Buoyed by 17% YoY volume growth and 10% improvement in ASP, BIL's Q4 revenue came in at Rs 17bn (+29% YoY) – ahead of our estimate. An above-expected gross margin further supported operational performance, leading to 360bps YoY EBITDA margin expansion to 31% (27.4% est.). EBITDA and adj. PAT both increased 45% YoY to Rs 5.4bn and Rs 3.7bn respectively.

**Robust volume guidance:** Management has guided for volume sales of 250k-265k MT for FY22, implying 10-17% growth over FY21. EBITDA margin is also expected to remain rangebound at 28-30% despite raw material cost headwinds. Management expects costs to increase 5-6% QoQ in Q1FY22 and has taken cumulative price hikes of ~4% in CY21.

Maintain SELL on high valuations: We scale up FY22/FY23 EPS estimates by 22%/16% to incorporate higher volume growth and margin assumptions. Over FY21-FY23, we pencil in a revenue/EBITDA/PAT CAGR of 12%/7%/8% for BIL. Ascribing an unchanged 22x FY23E P/E multiple to the stock – in line with its 5Y average – we arrive at a new Mar'22 TP of Rs 1,550 (vs. Rs 1,340). BIL is trading at an expensive 27x FY23E EPS – retain SELL.

### **KEY FINANCIALS**

Y/E 31 Mar	FY19A	FY20A	FY21P	FY22E	FY23E
Total revenue (Rs mn)	52,445	47,825	57,579	68,594	72,709
EBITDA (Rs mn)	13,125	12,494	17,855	19,332	20,492
Adj. net profit (Rs mn)	7,820	9,450	11,554	12,522	13,580
Adj. EPS (Rs)	40.5	48.9	59.8	64.8	70.3
Adj. EPS growth (%)	5.8	20.8	22.3	8.4	8.5
Adj. ROAE (%)	16.7	18.8	19.2	17.9	16.8
Adj. P/E (x)	46.9	38.8	31.7	29.3	27.0
EV/EBITDA (x)	28.7	30.0	21.0	19.4	18.3

Source: Company, BOBCAPS Research | P - Provisional

### Auto Components

15 May 2021

Mayur Milak | Nishant Chowhan, CFA research@bobcaps.in

Ticker/Price	BIL IN/Rs 1,896
Market cap	US\$ 5.0bn
Shares o/s	193mn
3M ADV	US\$13.4mn
52wk high/low	Rs 1,965/Rs 915
Promoter/FPI/DII	58%/12%/18%
Source: NSE	

### STOCK PERFORMANCE









GREENPANEL

Construction Materials

14 May 2021

# Stellar performance, maintain BUY

Greenpanel Industries' (GREENP) consolidated Q4FY21 revenue grew 64% YoY aided by a 63%/65% increase in the MDF/plywood segments. Operating margin (ex-forex gains) expanded 375bps YoY, spurring EBITDA growth of 93% YoY. Management has guided for further net debt reduction by Rs 1.5bn in FY22. We raise FY22-FY23 PAT by ~5% each and hike our target P/E to 18x (vs. 15x) due to material improvement in balance sheet, return ratios and profitability. Maintain BUY with a revised Mar'22 TP of Rs 295 (vs. Rs 235).

Strong volume growth: GREENP's revenue grew 64% YoY to Rs 3.9bn, with MDF up 63% as the segment's volumes climbed 54%. In plywood, revenue rose 65% YoY as volumes surged 58%. The consolidated print is commendable as the company had a strong base quarter when growth was up 36% YoY. Per management, Q1FY22 could see lockdown headwinds despite a decent April. GREENP has guided for further net debt reduction of Rs 1.5bn in FY22 (~Rs 1.7bn reduction in FY21). Working capital declined 10 days to 35 in FY21.

**Robust profitability:** EBITDA margin (ex-forex gains) expanded 375bps YoY to 24.6% aided by higher MDF/plywood profitability and better capacity utilisation, resulting in EBITDA/PBT growth of 93%/200% YoY. MDF margins rose 620bps YoY to 28.6% backed by better utilisation; plywood saw 710bps expansion to 15.5% due to cost optimisation and lower wastage. Management believes these margins are sustainable if utilisation levels are maintained.

Maintain BUY: GREENP had a robust FY21 and has strong demand tailwinds when markets reopen due to growing acceptance of readymade furniture and shift of the low-cost plywood market to MDF. Reiterate BUY on strong growth prospects and an improving debt and return ratio profile. Our Mar'22 TP of Rs 295 is based on 18x FY23E P/E.

### **KEY FINANCIALS**

		A FY21P	FY22E	FY23E
Total revenue (Rs mn) 5,	991 8,76	6 10,208	13,278	15,782
EBITDA (Rs mn)	774 1,43	2 2,034	3,056	3,730
Adj. net profit (Rs mn)	228 25	3 778	1,482	1,998
Adj. EPS (Rs)	1.9 2	.1 6.3	12.1	16.3
Adj. EPS growth (%)	NA 11.	0 207.4	90.6	34.8
Adj. ROAE (%)	7.1 3	9 11.2	18.4	20.4
Adj. P/E (x) 12	.9.3 116	4 37.9	19.9	14.7
EV/EBITDA (x)	NA 22	6 17.2	11.2	8.7

Source: Company, BOBCAPS Research | P - Provisional

## Arun Baid

research@bobcaps.in

Ticker/Price	GREENP IN/Rs 240
Market cap	US\$ 402.0mn
Shares o/s	123mn
3M ADV	US\$1.6mn
52wk high/low	Rs 245/Rs 24
Promoter/FPI/DII	53%/4%/43%
Source: NSE	

### **STOCK PERFORMANCE**





# **SELL** TP: Rs 1,580 | ❤ 12%

MPHASIS

IT Services

14 May 2021

Ruchi Burde | Seema Nayak

research@bobcaps.in

# DXC drag to continue; cut to SELL

Mphasis (MPHL) reported dollar revenue growth of 1.8% QoQ in Q4FY21, underperforming our estimate. Growth was dragged down by a slow pickup in direct channel business, which grew 3% QoQ USD. EBIT margin at 16.1% (16.5% est.) declined 30bps QoQ. We prune FY22/FY23 EPS by 1%/2% and roll forward to a revised Mar'22 TP of Rs 1,580 (vs. Rs 1,550), based on an unchanged 17x P/E. Considering the laggardly performance vis-à-vis peers and non-renewal of DXC's MRC, we downgrade the stock to SELL (vs. REDUCE).

**BCM growth declines:** MPHL's Q4 revenue grew 1.8% QoQ USD/2% CC, underperforming our estimate of 2.7%. The banking and capital markets (BCM) vertical contracted 4.3% vs. 1% growth in Q3 in INR terms. DXC revenue continued to slide, falling 7.2% QoQ USD. Growth now relies entirely on the direct-international segment (86% of revenue) as the minimum revenue commitment (MRC) with DXC ends in Sep'21. EBIT margin at 16.1% was down 30bps QoQ. Management expects the upward bias in EBIT margin to continue as higher demand for offshore services aids structural gains.

**Deal pipeline strong:** TCV stood at US\$ 245mn vs. US\$ 247mn in Q3. MPHL bagged a large 10-year deal worth ~US\$ 250mn in the BFSI vertical. The pipeline remains strong, growing 55% YoY, and is now tilted towards large contracts which are transformation-led and integrated in nature.

**Cut to SELL on DXC headwinds:** DXC channel business continues to decline and there is little hope that the MRC will be renewed after Sep'21. MPHL has been able to mitigate its decline in DXC revenue (-43% YoY USD in Q4) with growth in the direct channel (+21% YoY), but the negative impact from DXC remains evident, leading to a subpar quarterly performance. We thus move to SELL from REDUCE.

### **KEY FINANCIALS**

		FY21P	FY22E	FY23E
Total revenue (Rs mn) 77,311	88,436	97,223	112,897	130,391
EBITDA (Rs mn) 13,240	16,505	18,028	22,187	25,663
Adj. net profit (Rs mn) 10,734	11,849	12,167	14,890	17,417
Adj. EPS (Rs) 57.7	63.7	65.4	80.0	93.6
Adj. EPS growth (%) 30.9	10.4	2.7	22.4	17.0
Adj. ROAE (%) 20.0	21.4	19.7	22.0	23.8
Adj. P/E (x) 31.2	28.3	27.5	22.5	19.2
EV/EBITDA (x) 25.1	20.2	18.6	15.1	13.0

Source: Company, BOBCAPS Research | P - Provisional

Ticker/Price	MPHL IN/Rs 1,799
Market cap	US\$ 4.6bn
Shares o/s	186mn
3M ADV	US\$ 12.0mn
52wk high/low	Rs 1,883/Rs 786
Promoter/FPI/DII	52%/29%/14%
Source: NSE	

### STOCK PERFORMANCE







# Disclaimer

#### Recommendation scale: Recommendations and Absolute returns (%) over 12 months

BUY - Expected return >+15%

**ADD** – Expected return from >+5% to +15%

**REDUCE –** Expected return from -5% to +5%

SELL - Expected return <-5%

Note: Recommendation structure changed with effect from 1 January 2018 (Hold rating discontinued and replaced by Add / Reduce)

Our recommendation scale does not factor in short-term stock price volatility related to market fluctuations. Thus, our recommendations may not always be strictly in line with the recommendation scale as shown above.

#### **Rating distribution**

As of 30 April 2021, out of 90 rated stocks in the BOB Capital Markets Limited (BOBCAPS) coverage universe, 43 have BUY ratings, 16 have ADD ratings, 5 are rated REDUCE and 26 are rated SELL. None of these companies have been investment banking clients in the last 12 months.

#### Analyst certification

Each of the analysts mentioned in this research report certify, with respect to the sections of the report for which they are responsible, that (1) all of the views expressed in this report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOBCAPS.

#### Important disclosures

This product is a compilation of previously published research notes. To view the complete report along with the associated Analyst certifications and Company-specific disclosures, please click on the hyperlink accompanying each excerpt.

#### General disclaimers

BOBCAPS is engaged in the business of Institutional Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS has obtained registration as a Research Entity under SEBI (Research Analysts) Regulations, 2014, having registration No.: INH00000040 valid till 03 February 2025. BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities — that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such.

# **FIRST LIGHT**



Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may act as market makers or assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

In the US, this material is only for Qualified Institutional Buyers as defined under rule 144(a) of the Securities Act, 1933. No part of this document may be distributed in Canada or used by private customers in the United Kingdom.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

#### Other disclosures

BOBCAPS does not have any financial interest in the subject company. BOBCAPS does not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS is not engaged in any market making activities for the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.